Evidence map›Paper›PMID 33911591›Full record

ArticleAnnals of dermatology2019

A Report of 13 Cases of Merkel Cell Carcinoma: Single-Center Experience and Review of the Literature.

Serkan Yazici, Elif Irmak Yazici, Saduman Balaban Adim, Emel Bulbul Baskan, Kenan Aydoğan, Hayriye Saricaoğlu

Abstract read
In one paragraph

Article in Annals of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Serkan YaziciDepartment of Dermatology and Venereology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0001-6407-0962
Elif Irmak YaziciDepartment of Dermatology and Venereology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0001-7708-8483
Saduman Balaban AdimDepartment of Pathology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0002-8243-5440
Emel Bulbul BaskanDepartment of Dermatology and Venereology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0002-0144-3263
Kenan AydoğanDepartment of Dermatology and Venereology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0002-0193-1128
Hayriye SaricaoğluDepartment of Dermatology and Venereology, Uludag University School of Medicine, Bursa, Turkey.ORCID https://orcid.org/0000-0003-3801-2835

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is limited data knowledge of Merkel cell carcinoma (MCC) in Turkey aside from a few case reports.

objectiveThe aim of this study was to describe the clinical characteristics, demographic features, therapeutic parameters, and outcome of primary cutaneous MCC cases from Turkey.

methodsDigital medical records of the 13 MCC patients who were followed-up at a tertiary referral center were retrospectively analyzed. Clinic, demographic, tumor characteristics, and survival of the patients were retrieved.

resultsMost of our patients were elderly. Female predominance was noticed. The most common primary site of the tumors was the lower extremities. The overall survival was 42 months, 68% at first year, 68% at third years, and 29% at fifth years.

conclusionThis is the first largest report from Turkish population with female predominance, and lower extremity tendency.

Indexed as

MechanoreceptorMerkel cellMerkel cell carcinomaNeuroendocrine carcinomaPathogenesisPrognosisTrabecular carcinoma

Identifiers

PMID33911591
PMCPMC7992734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.